MicroRNA 16-2 (miR-16-2)

MicroRNA 16-2 (miR-16-2) is a short, non-coding RNA molecule belonging to the microRNA (miRNA) family, specifically classified as a non-coding RNA gene[1]. It is involved in *post-transcriptional regulation of gene expression* by binding to target messenger RNAs (mRNAs) in the RNA-induced silencing complex (RISC), resulting in mRNA destabilization or translational inhibition[1]. miR-16-2 shares a highly conserved sequence with miR-16-1, and mature miR-16-2 is functionally similar to miR-16-1 (often described collectively as miR-16-5p)[4]. \nThis miRNA is implicated in the regulation of key cellular processes including cell cycle progression, apoptosis, cell proliferation, and differentiation[3][4]. Its dysregulation has been prominently linked to several diseases, notably *chronic lymphocytic leukemia (CLL)*—where loss or downregulation of the miR-15a/16-1 cluster leads to overexpression of the anti-apoptotic BCL2 protein and resistance to apoptosis[2][3]—and to fibrosis in various tissues including liver, lung, heart, and kidney[4]. \nWhile no direct drug interactions are documented, miR-16 (including miR-16-2) and its clusters are under investigation as therapeutic targets or biomarkers in cancer and fibrotic diseases due to their central roles in apoptosis and cell cycle control[3][4]. The broad regulatory function of miR-16-2 means that therapeutic targeting could pose risks of off-target effects by impacting multiple cellular pathways.

Other names

hsa-mir-16-2MIRN16-2mir-16-2mir-16-3MIR16-2

Post-transcriptional suppression of target mRNAs by inclusion in RNA-induced silencing complex (RISC), leading to mRNA destabilization or translational inhibition